NERV (Minerva Neurosciences) ROCE %: -72.01% (As of Mar. 2026)


NERV Minerva Neurosciences Inc NERV
32 GF Score
Price $4.32
! 1 Warning Sign
View Full Analysis

What is Minerva Neurosciences ROCE %?

Minerva Neurosciences NERV +0.12% 32 ROCE % is -72.01% as of Mar. 2026. GuruFocus rates NERV with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Minerva Neurosciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -72.01%.

Minerva Neurosciences  (NAS:NERV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Minerva Neurosciences ROCE % Related Terms

Minerva Neurosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Minerva Neurosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Neurosciences ROCE % Chart

Minerva Neurosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -70.49 -38.59 -40.50 13.66 -451.47

Minerva Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.92 -44.38 -41.18 -1,873.96 -72.01
NERV
32GF Score
Minerva Neurosciences Inc NERV
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minerva Neurosciences ROCE % Calculation

Minerva Neurosciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-293.423/( ( (37.144 - 2.837) + (97.969 - 2.29) )/ 2 )
=-293.423/( (34.307+95.679)/ 2 )
=-293.423/64.993
=-451.47 %

Minerva Neurosciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-66.688/( ( (97.969 - 2.29) + (94.027 - 4.482) )/ 2 )
=-66.688/( ( 95.679 + 89.545 )/ 2 )
=-66.688/92.612
=-72.01 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -72.01% mean?
Minerva Neurosciences (NERV) has a ROCE % of -72.01% as of Mar. 2026.
Is Minerva Neurosciences' ROCE % too high?
Minerva Neurosciences' current ROCE % is -72.01%. Overall, Minerva Neurosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Minerva Neurosciences' ROCE % compare to YDES and CAMP?
Minerva Neurosciences' ROCE % of -72.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Minerva Neurosciences's current ROCE % is -72.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Neurosciences stock overvalued right now?
Minerva Neurosciences (NERV) has a current ROCE % of -72.01%. The current ROCE % is -72.01%. Minerva Neurosciences' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Minerva Neurosciences (NERV), the current ROCE % is -72.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Neurosciences Business Description

Other Exchanges 4MNA:Germany
Address 1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
32GF Score

Get the complete analysis for NERV

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.32
Price